Header Logo

Connection

JAMES C YAO to Male

Back to Details
This is a "connection" page, showing publications JAMES C YAO has written about Male.
JAMES C YAO
Connection Strength
0.896
Male
  1. Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market. JNCI Cancer Spectr. 2021 08; 5(4).
    View in: PubMed
    Score: 0.023
  2. Recurrence of Metastatic Pro-insulinoma Nearly 50?Years After Subtotal Pancreatectomy. J Gastrointest Cancer. 2019 Jun; 50(2):345-348.
    View in: PubMed
    Score: 0.020
  3. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas. 2019 03; 48(3):381-386.
    View in: PubMed
    Score: 0.020
  4. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocr Relat Cancer. 2019 04 01; 26(4):391-403.
    View in: PubMed
    Score: 0.020
  5. CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents. Abdom Radiol (NY). 2018 07; 43(7):1661-1669.
    View in: PubMed
    Score: 0.019
  6. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 2018 02 15; 124(4):807-815.
    View in: PubMed
    Score: 0.018
  7. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 01; 3(10):1335-1342.
    View in: PubMed
    Score: 0.018
  8. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol. 2017 May 20; 35(15):1695-1703.
    View in: PubMed
    Score: 0.017
  9. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017 04; 18(4):525-534.
    View in: PubMed
    Score: 0.017
  10. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol. 2016 11 10; 34(32):3906-3913.
    View in: PubMed
    Score: 0.017
  11. Everolimus in ileum neuroendocrine tumours - Authors' reply. Lancet. 2016 Jul 16; 388(10041):236-7.
    View in: PubMed
    Score: 0.017
  12. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer. 2016 09; 24(9):3695-703.
    View in: PubMed
    Score: 0.016
  13. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist. 2016 Mar; 21(3):308-13.
    View in: PubMed
    Score: 0.016
  14. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 05; 387(10022):968-977.
    View in: PubMed
    Score: 0.016
  15. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1656-65.
    View in: PubMed
    Score: 0.016
  16. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2015 Jun; 22(3):431-41.
    View in: PubMed
    Score: 0.015
  17. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 2015 Mar; 44(2):190-7.
    View in: PubMed
    Score: 0.015
  18. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015 Mar; 44(2):181-9.
    View in: PubMed
    Score: 0.015
  19. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014 Jul 01; 120(13):2039-49.
    View in: PubMed
    Score: 0.014
  20. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2014 Feb; 21(1):22-7.
    View in: PubMed
    Score: 0.014
  21. Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values. Radiology. 2013 Dec; 269(3):758-67.
    View in: PubMed
    Score: 0.014
  22. Improving the success rate of gluteal intramuscular injections. Pancreas. 2013 Jul; 42(5):878-82.
    View in: PubMed
    Score: 0.013
  23. A rationale for multidisciplinary care in treating neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2012 Aug; 19(4):306-13.
    View in: PubMed
    Score: 0.013
  24. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012 Apr; 41(3):461-6.
    View in: PubMed
    Score: 0.012
  25. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011 Dec; 96(12):3741-9.
    View in: PubMed
    Score: 0.012
  26. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol. 2011 Mar; 196(3):569-76.
    View in: PubMed
    Score: 0.011
  27. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10; 364(6):514-23.
    View in: PubMed
    Score: 0.011
  28. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 01; 29(7):934-43.
    View in: PubMed
    Score: 0.011
  29. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg. 2010 Jun; 251(6):1117-21.
    View in: PubMed
    Score: 0.011
  30. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010 Jan 01; 28(1):69-76.
    View in: PubMed
    Score: 0.010
  31. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009 Jan 08; 360(2):195-7.
    View in: PubMed
    Score: 0.010
  32. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008 Sep 10; 26(26):4311-8.
    View in: PubMed
    Score: 0.010
  33. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer. 2008 Aug 15; 123(4):867-73.
    View in: PubMed
    Score: 0.010
  34. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20; 26(18):3063-72.
    View in: PubMed
    Score: 0.009
  35. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008 Apr; 17(4):959-65.
    View in: PubMed
    Score: 0.009
  36. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23.
    View in: PubMed
    Score: 0.009
  37. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008 Jan; 19(1):145-51.
    View in: PubMed
    Score: 0.009
  38. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007 Dec; 14(12):3492-500.
    View in: PubMed
    Score: 0.009
  39. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40.
    View in: PubMed
    Score: 0.009
  40. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005 Oct 15; 104(8):1590-602.
    View in: PubMed
    Score: 0.008
  41. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103.
    View in: PubMed
    Score: 0.008
  42. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 01; 22(23):4762-71.
    View in: PubMed
    Score: 0.007
  43. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4109-17.
    View in: PubMed
    Score: 0.007
  44. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist. 2024 Jun 03; 29(6):e803-e810.
    View in: PubMed
    Score: 0.007
  45. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark. 2024; 41(1):83-91.
    View in: PubMed
    Score: 0.007
  46. Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured. J Natl Cancer Inst. 2022 10 06; 114(10):1392-1399.
    View in: PubMed
    Score: 0.006
  47. Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors. Int J Mol Sci. 2022 Jan 31; 23(3).
    View in: PubMed
    Score: 0.006
  48. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
    View in: PubMed
    Score: 0.006
  49. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol. 2002; 13 Suppl 4:7-12.
    View in: PubMed
    Score: 0.006
  50. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 12; 22(12):1752-1763.
    View in: PubMed
    Score: 0.006
  51. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology. 2021 06; 73(6):2278-2292.
    View in: PubMed
    Score: 0.006
  52. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas. 2021 04 01; 50(4):506-512.
    View in: PubMed
    Score: 0.006
  53. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2022; 112(1):34-42.
    View in: PubMed
    Score: 0.006
  54. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846.
    View in: PubMed
    Score: 0.006
  55. Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology. 2021; 111(9):850-862.
    View in: PubMed
    Score: 0.006
  56. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas. 2019 Nov/Dec; 48(10):1373-1379.
    View in: PubMed
    Score: 0.005
  57. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118.
    View in: PubMed
    Score: 0.005
  58. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877.
    View in: PubMed
    Score: 0.005
  59. Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. Pancreas. 2019 04; 48(4):510-513.
    View in: PubMed
    Score: 0.005
  60. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics. 2018 08; 36(8):1005-1013.
    View in: PubMed
    Score: 0.005
  61. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol. 2018 Jun; 25(6):1709-1715.
    View in: PubMed
    Score: 0.005
  62. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Na?ve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2018 07; 23(7):766-e90.
    View in: PubMed
    Score: 0.005
  63. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol. 2017 Dec; 40(6):555-560.
    View in: PubMed
    Score: 0.005
  64. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018 Jan; 109(1):174-181.
    View in: PubMed
    Score: 0.005
  65. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 10; 18(10):1411-1422.
    View in: PubMed
    Score: 0.004
  66. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
    View in: PubMed
    Score: 0.004
  67. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. Pancreas. 2017 07; 46(6):751-757.
    View in: PubMed
    Score: 0.004
  68. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017 12; 22(12):1451-1462.
    View in: PubMed
    Score: 0.004
  69. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology. 2018; 106(3):211-220.
    View in: PubMed
    Score: 0.004
  70. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
    View in: PubMed
    Score: 0.004
  71. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135.
    View in: PubMed
    Score: 0.004
  72. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery. 2017 03; 161(3):753-759.
    View in: PubMed
    Score: 0.004
  73. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016 Oct 25; 7(43):69916-69926.
    View in: PubMed
    Score: 0.004
  74. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2017 01; 21(1):155-163.
    View in: PubMed
    Score: 0.004
  75. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol (Oxf). 2016 09; 85(3):400-7.
    View in: PubMed
    Score: 0.004
  76. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016 Jun; 15(2):e1-7.
    View in: PubMed
    Score: 0.004
  77. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer. 2015 Dec; 22(6):933-40.
    View in: PubMed
    Score: 0.004
  78. Role and Operative Technique of Portal Venous Tumor Thrombectomy in Patients with Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2015 Nov; 19(11):2011-8.
    View in: PubMed
    Score: 0.004
  79. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
    View in: PubMed
    Score: 0.004
  80. Effect on perfusion values of sampling interval of computed tomographic perfusion acquisitions in neuroendocrine liver metastases and normal liver. J Comput Assist Tomogr. 2015 May-Jun; 39(3):373-82.
    View in: PubMed
    Score: 0.004
  81. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. Neuroendocrinology. 2015; 102(1-2):18-25.
    View in: PubMed
    Score: 0.004
  82. Expression of estrogen-induced genes and estrogen receptor ? in pancreatic neuroendocrine tumors: implications for targeted therapy. Pancreas. 2014 Oct; 43(7):996-1002.
    View in: PubMed
    Score: 0.004
  83. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer. 2014 Aug 02; 14:561.
    View in: PubMed
    Score: 0.004
  84. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014 Aug; 138(8):1027-36.
    View in: PubMed
    Score: 0.004
  85. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14.
    View in: PubMed
    Score: 0.004
  86. Effect of pre-enhancement set point on computed tomographic perfusion values in normal liver and metastases to the liver from neuroendocrine tumors. J Comput Assist Tomogr. 2014 Jul-Aug; 38(4):526-34.
    View in: PubMed
    Score: 0.004
  87. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9.
    View in: PubMed
    Score: 0.003
  88. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013 Jul; 37(7):1695-700.
    View in: PubMed
    Score: 0.003
  89. Clinical burden of illness in patients with neuroendocrine tumors. Pancreas. 2012 Oct; 41(7):1058-62.
    View in: PubMed
    Score: 0.003
  90. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res. 2012 Nov 15; 72(22):5683-91.
    View in: PubMed
    Score: 0.003
  91. Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2012 Sep; 199(3):602-8.
    View in: PubMed
    Score: 0.003
  92. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10; 378(9808):2005-2012.
    View in: PubMed
    Score: 0.003
  93. EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci. 2012 Mar; 57(3):791-800.
    View in: PubMed
    Score: 0.003
  94. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer. 2011 Feb; 18(1):171-80.
    View in: PubMed
    Score: 0.003
  95. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63.
    View in: PubMed
    Score: 0.003
  96. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15; 116(6):1446-53.
    View in: PubMed
    Score: 0.003
  97. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009 Mar 01; 15(5):1821-9.
    View in: PubMed
    Score: 0.002
  98. Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res. 2009 Feb 03; 28:14.
    View in: PubMed
    Score: 0.002
  99. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol. 2009 Jan; 16(1):42-50.
    View in: PubMed
    Score: 0.002
  100. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer. 2008 Aug 01; 113(3):461-9.
    View in: PubMed
    Score: 0.002
  101. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol. 2008 Oct; 15(10):2684-91.
    View in: PubMed
    Score: 0.002
  102. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan; 63(2):363-70.
    View in: PubMed
    Score: 0.002
  103. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008 Mar; 15(1):257-66.
    View in: PubMed
    Score: 0.002
  104. Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer. 2008 Jan; 47(1):84-92.
    View in: PubMed
    Score: 0.002
  105. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci. 2008; 38(3):195-209.
    View in: PubMed
    Score: 0.002
  106. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90.
    View in: PubMed
    Score: 0.002
  107. The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res. 2007 Aug 15; 13(16):4704-12.
    View in: PubMed
    Score: 0.002
  108. Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis. Endocr Relat Cancer. 2007 Jun; 14(2):483-92.
    View in: PubMed
    Score: 0.002
  109. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol. 2007 Jul; 20(7):802-10.
    View in: PubMed
    Score: 0.002
  110. [Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis]. Zhonghua Zhong Liu Za Zhi. 2007 Feb; 29(2):107-11.
    View in: PubMed
    Score: 0.002
  111. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan 01; 109(1):33-40.
    View in: PubMed
    Score: 0.002
  112. Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis. 2006; 23(7-8):401-10.
    View in: PubMed
    Score: 0.002
  113. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80.
    View in: PubMed
    Score: 0.002
  114. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul; 24(4):353-7.
    View in: PubMed
    Score: 0.002
  115. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006 May; 30(5):643-53.
    View in: PubMed
    Score: 0.002
  116. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Feb 01; 24(4):663-7.
    View in: PubMed
    Score: 0.002
  117. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol. 2005 Dec; 18(12):1632-40.
    View in: PubMed
    Score: 0.002
  118. Carcinoid tumors of the duodenum. Surgery. 2005 Dec; 138(6):971-7; discussion 977-8.
    View in: PubMed
    Score: 0.002
  119. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005 Oct 01; 23(28):6957-65.
    View in: PubMed
    Score: 0.002
  120. Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin Cancer Res. 2005 Aug 15; 11(16):5778-83.
    View in: PubMed
    Score: 0.002
  121. Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Mod Pathol. 2005 Aug; 18(8):1079-87.
    View in: PubMed
    Score: 0.002
  122. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res. 2005 Jun 01; 65(11):4809-16.
    View in: PubMed
    Score: 0.002
  123. Drastic down-regulation of Kr?ppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res. 2005 Apr 01; 65(7):2746-54.
    View in: PubMed
    Score: 0.002
  124. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64.
    View in: PubMed
    Score: 0.002
  125. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005 Feb 20; 23(6):1237-44.
    View in: PubMed
    Score: 0.002
  126. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1386-93.
    View in: PubMed
    Score: 0.002
  127. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):656-63.
    View in: PubMed
    Score: 0.002
  128. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer. 2005; 8(1):18-28.
    View in: PubMed
    Score: 0.002
  129. Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer. Clin Exp Metastasis. 2005; 22(3):205-13.
    View in: PubMed
    Score: 0.002
  130. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93.
    View in: PubMed
    Score: 0.002
  131. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36.
    View in: PubMed
    Score: 0.002
  132. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66.
    View in: PubMed
    Score: 0.002
  133. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004; 17(1):38-43.
    View in: PubMed
    Score: 0.002
  134. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004; 21(8):755-64.
    View in: PubMed
    Score: 0.002
  135. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003 Dec 15; 9(17):6371-80.
    View in: PubMed
    Score: 0.002
  136. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2.
    View in: PubMed
    Score: 0.002
  137. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003 Jul-Aug; 9(4):261-7.
    View in: PubMed
    Score: 0.002
  138. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol. 2003 Apr; 26(2):165-70.
    View in: PubMed
    Score: 0.002
  139. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001 Feb; 24(1):91-5.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.